Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduced expression of N-methyl-D-aspartate receptor and calcium signaling genes in gray matter is associated with cancer-related cognitive impairment.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

A hierarchical clinical fusion transformer model for personalized opioid treatment: Development and validation in diabetic surgical patients.

medRxiv : the preprint server for health sciences·2026
Same author

The Inverse Care Law in the Age of AI - Geographic Disparities in Health Care Technology Access.

NEJM AI·2026
Same author

Don't Cancer Doctors Offer Good-Quality Care?

JCO oncology practice·2026
Same author

What Utah's clinical AI sandbox reveals about independent oversight.

Nature medicine·2026
Same author

Building safer artificial intelligence mental health chatbots: a framework for transparency, evaluation, and shared accountability.

Journal of the American Medical Informatics Association : JAMIA·2026

Related Experiment Video

Updated: May 11, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.0K

Graph augmented transformers improve chemotherapy toxicity symptom extraction from clinical notes.

Elia Saquand1, Behzad Naderalvojoud1, Maximilian Schuessler2

  • 1Department of Medicine, Stanford University, Stanford, CA, USA.

Nature Communications
|April 28, 2026
PubMed
Summary

Detecting chemotherapy side effects is crucial. A new AI model, GAT-CN, uses clinical notes to better identify patient symptoms, improving cancer care and reducing healthcare burdens.

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.9K

Related Experiment Videos

Last Updated: May 11, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.0K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.9K

Area of Science:

  • Artificial Intelligence in Medicine
  • Computational Linguistics
  • Oncology

Background:

  • Chemotherapy is vital for cancer treatment but can cause adverse events, leading to significant healthcare costs.
  • Current methods using structured electronic health records (EHR) fail to capture the full spectrum of patient symptoms.
  • Clinical notes offer rich data but are difficult to analyze effectively.

Purpose of the Study:

  • To develop and evaluate an advanced AI model for improved extraction of chemotherapy-related toxicity symptoms from clinical notes.
  • To enhance the early detection and monitoring of adverse events associated with cancer chemotherapy.

Main Methods:

  • Developed Graph-Augmented Transformer for Clinical Notes (GAT-CN), integrating Bio+ClinicalBERT embeddings with GraphSAGE-learned heterogeneous clinical graphs.
  • Utilized transformer-based language models and graph neural networks to process and analyze unstructured clinical text.
  • Performed multi-symptom classification to assess model performance against transformer-only baselines.

Main Results:

  • GAT-CN achieved a weighted AUROC of 0.850 and AUPRC of 0.812 in multi-symptom classification, outperforming transformer-only models.
  • The model successfully identified additional diagnoses missed in structured EHR data, validated by manual annotation.
  • Demonstrated superior performance in extracting chemotherapy toxicity symptoms from narrative clinical data.

Conclusions:

  • Graph-augmented models significantly enhance the detection of patient symptoms from clinical narratives.
  • The GAT-CN model shows promise for earlier and more accurate monitoring of chemotherapy-related adverse events.
  • Integrating language models with graph neural networks offers a powerful approach to analyzing complex clinical text for improved patient outcomes.